Skip to main content

Table 1 Patient demographic and baseline clinical characteristics (safety population)

From: Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study

  Indacaterol 150 μg o.d.
N = 211
Placebo
N = 205
Age, in years, mean (SD) 62.9 (9.89) 63.2 (9.62)
Sex, n (%)   
   Male 108 (51.2) 110 (53.7)
   Female 103 (48.8) 95 (46.3)
Race, n (%)   
   Caucasian 194 (91.9) 191 (93.2)
   Black 12 (5.7) 10 (4.9)
   Asian 1 (0.5) 1 (0.5)
   Native American 2 (0.9) 1 (0.5)
   Other 2 (0.9) 2 (1.0)
Duration of COPD, in years, mean (SD) 6.6 (6.86) 7.3 (5.64)
Duration of COPD, in years, n (%)   
   <1 38 (18.0) 18 (8.8)
   1—5 74 (35.1) 69 (33.7)
   >5—10 57 (27.0) 69 (33.7)
   >10—15 23 (10.9) 30 (14.6)
   >15—20 9 (4.3) 12 (5.9)
   >20 10 (4.7) 7 (3.4)
Severity of COPD*, n (%)   
   At risk 0 (0.0) 1 (0.5)
   Mild 7 (3.3) 10 (4.9)
   Moderate 119 (56.4) 117 (57.1)
   Severe 84 (39.8) 76 (37.1)
   Very severe 1 (0.5) 1 (0.5)
Smoking history, n (%)   
   Ex-smoker 103 (48.8) 97 (47.3)
   Current smoker 108 (51.2) 108 (52.7)
Number of pack years, mean (SD) 53.5 (26.84) 60.5 (54.12)
FEV1 (L), mean (SD) 1.5 (0.53) 1.5 (0.51)
FEV1 (% predicted), mean (SD) 54.4 (13.38) 55.8 (14.08)
FEV1/FVC (%), mean (SD) 53.5 (9.84) 53.5 (10.36)
FEV1 reversibility (%), mean (SD) 16.4 (17.31) 16.6 (19.44)
Concomitant ICS, n (%) 61 (28.9) 70 (34.1)
  1. COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; ICS = inhaled corticosteroids.
  2. *As per GOLD 2005
  3. Pack years = total years of smoking multiplied by cigarette packs smoked per day
  4. Post-bronchodilator (within 30 min after inhaling 400 μg salbutamol)